Unknown

Dataset Information

0

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.


ABSTRACT: BACKGROUND:In adults with primary focal segmental glomerulosclerosis (FSGS), daily prednisone may induce complete remissions (CR) and partial remissions (PR), but relapses are frequent and adverse events are common. METHODS:We carried out 2 open-label, uncontrolled trials to explore the efficacy and tolerability of pulse oral dexamethasone as an alternative to daily prednisone. We enrolled adult patients with proteinuria > 3.5 g/day despite the use of renin-angiotensin-aldosterone blockade. In the first trial, we enrolled 14 subjects with FSGS and administered 4 dexamethasone doses (25 mg/m2) daily for 4 days, repeated every 28 days over 32 weeks. The second trial involved a more intensive regimen. Eight subjects received 4 dexamethasone doses of 50 mg/m2 every 4 weeks for 12 weeks, followed by 4 doses of 25 mg/m2 every 4 weeks for 36 weeks; subjects were randomized to 2 doses every 2 weeks or 4 doses every 4 weeks. RESULTS:In the first trial, we enrolled 13 subjects with FSGS and 1 with minimal change disease and found a combined CR and PR rate of 36%. In the second trial, we enrolled 8 subjects. The combined CR and PR rate was 29%. Analysis combining both trials showed a combined CR and PR rate of 33%. Adverse events were observed in 32% of subjects, with mood symptoms being most common. There were no serious adverse events related to the study. CONCLUSION:We conclude that high dose oral dexamethasone is well tolerated by adults with idiopathic nephrotic syndrome and may have some efficacy.

SUBMITTER: Cho ME 

PROVIDER: S-EPMC6677391 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Cho Monique E ME   Branton Mary H MH   Smith David A DA   Bartlett Linda L   Howard Lilian L   Reynolds James C JC   Rosenstein Donald D   Sethi Sanjeev S   Nava M Berenice MB   Barisoni Laura L   Fervenza Fernando C FC   Kopp Jeffrey B JB  

American journal of nephrology 20190409 5


<h4>Background</h4>In adults with primary focal segmental glomerulosclerosis (FSGS), daily prednisone may induce complete remissions (CR) and partial remissions (PR), but relapses are frequent and adverse events are common.<h4>Methods</h4>We carried out 2 open-label, uncontrolled trials to explore the efficacy and tolerability of pulse oral dexamethasone as an alternative to daily prednisone. We enrolled adult patients with proteinuria > 3.5 g/day despite the use of renin-angiotensin-aldosterone  ...[more]

Similar Datasets

| S-EPMC6242849 | biostudies-other
| S-EPMC7391815 | biostudies-literature
| S-EPMC4876225 | biostudies-literature
| S-EPMC3358759 | biostudies-literature
| S-EPMC3162962 | biostudies-literature
| S-EPMC5531573 | biostudies-other
| S-EPMC9562314 | biostudies-literature
| S-EPMC2615726 | biostudies-literature
| S-EPMC6868353 | biostudies-literature
| S-EPMC4822672 | biostudies-literature